USP <1132> Residual Host Cell Protein Measurement in Biopharmaceuticals

USP General Chapter <1132> provides a comprehensive, informational framework for controlling residual host cell proteins (HCPs)—process-related impurities from the production cell line (e.g., CHO, E. coli). It emphasizes the ELISA-based strategy as the primary method, supplemented with orthogonal approaches to address blind spots. HCPs are managed as process impurities; total and/or specific HCPs may be designated as critical quality attributes (CQAs) when risk assessment shows a potential impact on product safety or efficacy. USP <1132.1>, effective May 1, 2025, extends this framework with detailed guidance for MS-based HCP analysis.

Scope: Guidance on assay development, optimization, validation/qualification, orthogonal characterization, and lifecycle monitoring of residual HCPs across development and commercial stages.

Philosophy: HCP control should be risk-based and lifecycle-driven, aligned with ICH Q6B and other regulatory standards.

Primary Method – Process-Specific HCP ELISA

• Preferred tool: Polyclonal, process-specific sandwich ELISA.
• Critical reagent: Antibody reagent breadth and quality determine assay performance.
• Commercial/platform ELISAs: May be used if demonstrated fit-for-purpose.

Coverage Assessment – Evidence of Fitness

• Demonstrates that ELISA antibodies detect a broad, representative subset of process HCPs.
• Traditional methods: 1D/2D SDS-PAGE with Western blot.
• Modern methods: immunoaffinity capture with 2D-DIGE or MS.
• Coverage should be reassessed if process or reagent changes occur.

Validation / qualification characteristics (ELISA). In addition to general analytical characteristics, <1132> highlights bioassay-relevant aspects:
• Accuracy (spike-recovery) using an appropriate HCP standard in the product matrix.
• Precision (repeatability and intermediate precision).
• Sensitivity/reportable range (LOD/LOQ) appropriate to low-level HCP release expectations (typically expressed as ng HCP per mg product, i.e., ppm).
• Dilutional linearity to confirm mitigation of matrix interference at high drug concentrations.
• System suitability / controls (e.g., calibrated standard, positive/negative controls) to verify run acceptability.

Orthogonal methods are required for comprehensive understanding.

<1132> and <1132.1> stress that a single ELISA is not sufficient for full characterization. Orthogonal methods—2D gel/Western or immunoaffinity-enrichment workflows and LC-MS/MS—are used to identify/track individual HCPs, probe ELISA blind spots, and support risk assessment for persistent/problematic proteins (e.g., proteases, lipases).

Lifecycle management / change control

HCP profiles should be assessed through development, characterization, and after significant process or reagent changes; trending supports specification-setting and continued process verification.

Acceptance criteria (specifications) for total and/or specific HCPs are risk-based, reflecting clinical experience, process capability, and knowledge of identified HCPs. When critical reagents are replaced, bridging to demonstrate comparable assay capability is expected.

Positioning with recent USP content. While <1132> focuses on ELISA-centric strategy, USP <1132.1> (official in USP–NF 2025 Issue 1, effective May 1, 2025) provides detailed guidance for MS-based HCP measurement, including method development, quantification, validation expectations, and typical use cases in risk assessment.